276 related articles for article (PubMed ID: 20145179)
1. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
4. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
[TBL] [Abstract][Full Text] [Related]
5. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
6. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
8. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
[TBL] [Abstract][Full Text] [Related]
9. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII.
Barrett JM; Rovedo MA; Tajuddin AM; Jilling T; Macoska JA; MacDonald J; Mangold KA; Kaul KL
Prostate; 2006 May; 66(6):632-50. PubMed ID: 16388503
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
18. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
[TBL] [Abstract][Full Text] [Related]
19. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
